Context: Supplementation with high-dose docosahexaenoic acid (DHA) increases serum low-density lipoprotein (LDL) cholesterol (LDL-C) concentrations more than high-dose eicosapentaenoic acid (EPA). The mechanisms underlying this difference are unknown.
concentrations (1) . The extent to which different LCn3-PUFAs have distinct effects on CVD risk also remains questionable because previous studies have shown that DHA is more potent than EPA in modulating cardiovascular risk factors, including increasing LDL-C concentrations (3, 4) . To the best of our knowledge, no study has yet examined how DHA and EPA influence the mechanisms underlying their differential effect on several LDL features, including LDL-C concentrations and, hence, CVD risk.
It has been stressed that the cholesterol content of LDL represents only one of several features of this complex lipoprotein, which is heterogeneous in size, charge, and protein content (5, 6) . Different immunochemically defined LDL subclasses are thought to have distinct metabolisms and atherogenicity (6) . Specifically, small and dense LDL (sdLDL) consists largely of apolipoprotein (apo)-CIIIcontaining lipoproteins that originate from the remodeling in plasma of apo-CIII-rich very-low-density lipoprotein (VLDL) (7) . sdLDLs have also been consistently associated with an increased risk of developing CVD, independent of the LDL-C concentration (8) . Data from a limited number of trials have suggested that, unlike EPA, high-dose DHA increases LDL particle size (9) . In other studies, LCn3-PUFA supplementation (4 g/d) in hypertriglyceridemic men had no substantial impact on the features of the LDL size phenotype. However, this might have been because DHA and EPA were given in combination (10, 11) . Although the clinical relevance of the potential differences between DHA and EPA in modulating LDL particle size is unclear, data have suggested that both LCn3-PUFAs might differentially influence LDL metabolism.
Previous studies have investigated the effect of an LCn3-PUFA-rich diet or supplementation on the kinetic of apoB100-containing lipoproteins. Ooi et al. (12) have shown that a high-fish diet providing 1.23 g/d of EPA and DHA reduced the TG-rich lipoprotein (TRL) apoB100 concentration and production rate (PR) compared with a low-fish diet in elderly men and women with moderate hyperlipidemia. These studies also showed that the highfish diet decreased TRL apoB100-direct catabolism, rechanneling TRL toward conversion into LDL and, hence, increasing the LDL PR. These data have been reproduced in other studies that used fish oils as supplements (13) (14) (15) (16) (17) . Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by degrading cellular LDL receptors, blunting the clearance of LDL from the circulation (18) . LCn3-PUFAs have been shown to decrease PCSK9 concentrations in several studies (19, 20) , which should, in theory, be associated with increased LDL clearance and, hence, reduced serum LDL-C. To the best of our knowledge, no study has yet compared the effect of high-dose supplementation with DHA and EPA on the kinetics of apoB100-containing lipoproteins and PCSK9 as key determinants of LDL-C concentrations.
The objective of the present study was, therefore, to examine the mechanisms underlying the differential effect of DHA and EPA supplementation on LDL features, including the LDL-C concentrations in men and women at risk of CVD. Specifically, we compared the effect of high doses of DHA and of EPA on the intravascular kinetics of apoB100-containing lipoproteins, VLDL apoCIII, LDL particle size distribution, and PCSK9 levels. We hypothesized that DHA has favorable effects on LDL size features compared with EPA and that changes in the intravascular kinetics of LDL are also different between DHA and EPA, thereby partly explaining the different effect of the two LCn3-PUFAs on the serum LDL-C concentrations.
Materials and Methods

Study design
Details of the study design have been previously reported (4) . In brief, the present study used a double-blind randomized, controlled crossover design with three treatment phases: phase 1, DHA; phase 2, EPA; phase 3, corn oil as the control. Each treatment phase had a median duration of 10 weeks, separated by a 9-week washout period. The participants were randomized to one of six treatment sequences and received supplementation with three identical 1-g capsules of .90% purified LCn3-PUFA daily, providing either 2.7 g/d of DHA or 2.7 g/d of EPA. Corn oil was used as the control (0 g/d of DHA plus EPA). LCn3-PUFA supplements were formulated as re-esterified TG and provided by Douglas Laboratories (Pittsburgh, PA). The participants were instructed to maintain a constant body weight during the course of the study and were counseled on how to exclude fatty fish (including salmon, tuna, mackerel, and herring), other LCn3-PUFA supplements, flax products, walnuts, and LCn3-PUFA-enriched products during the three study phases. The primary outcome of the present study was the change in C-reactive protein (CRP) with DHA and EPA supplementation (4). All participants signed an informed consent document that had been approved by local ethics committees at the beginning of the study, and the study protocol was registered at ClinicalTrials.gov (NCT01810003) on March 4, 2013.
Study population
The primary eligibility criteria were abdominal obesity using the International Diabetes Federation sex-specific cutoffs ($80 cm for women, $94 cm for men) (21) and a screening plasma CRP concentration .1 mg/L but ,10 mg/L. The participants had to be otherwise healthy. Adult participants (aged 18 to 70 years) were recruited at the Institute of Nutrition and Functional Foods. Their body weight had to be stable for $3 months before randomization. The exclusion criteria were plasma CRP .10 mg/L at screening, extreme dyslipidemia such as familial hypercholesterolemia, a personal history of CVD (coronary heart disease, cerebrovascular disease, or peripheral arterial disease), use of medications or substances known to affect inflammation (e.g., steroids, binging alcohol), and the use of LCn3-PUFA supplements within 2 months of study onset. However, individuals taking lipid-lowering drugs for .1 month were eligible.
Anthropometry
Anthropometric measures, including waist and hip circumferences, were measured according to standardized procedures before and after each study phase (22) . Body weight was measured before each kinetic protocol.
Compliance
Compliance to supplementation was assessed by counting the supplements that were returned to the study coordinators by the participants (4). The DHA and EPA content in red blood cells was also used as another proxy of compliance for all participants (23) .
Laboratory analyses
Blood samples were collected after a 12-hour overnight fast on 2 consecutive days at the end of each treatment phase. The mean of the two measurements was used in the analyses of the LDL features and blood glucose. The total apoB100, apoCIII, PCSK9, and insulin concentrations were measured once after each treatment phase. The serum total apoB100, apoCIII, and PCSK9 concentrations were measured using commercial ELISA kits [catalog no. A70102 (Alerchek Inc., Springvale, ME), catalog no. EA8133-1 (Assaypro LLC, St. Charles, MO), catalog no. CY-8079 (CircuLex, Nagano, Japan)]. Serum LDL-C concentrations were calculated using the Friedewald equation. Nondenaturing 2% to 16% polyacrylamide gradient gel electrophoresis was used to characterize various features of the LDL particle size phenotype (24) , including the LDL peak particle size and mean LDL particle size and the proportion of LDL in the various size categories. Fasting blood glucose levels were measured using colorimetry, and insulin concentrations were measured using electrochemiluminescence (Roche Diagnostics, Indianapolis, IN). Finally, the homeostatic model assessment of insulin resistance was measured using the formula developed by Matthews et al. (25) . All personnel involved in the measurements of the study outcomes were unaware of the treatments.
Experimental protocol for in vivo stable isotope kinetics
Kinetic studies using primed-constant infusion of deuterated leucine were performed at the end of each treatment in a subsample of the participants. The participants in the kinetic studies were recruited as a part of the general recruitment process in the project, until 20 participants had been reached. The participants underwent a primed-constant infusion of L- [5,5,5-D 3 ] leucine while kept in a constant fed state to determine the kinetics of apoB100. Starting at 7:00 AM, the participants received one small standardized snack every 30 minutes for 15 hours, each containing 1/30th of their estimate daily food intake, according to the Harris-Benedict equation (26) , with 15% of the calories from proteins, 45% from carbohydrates, and 40% from fat. The snacks were the same for each treatment. At 10:00 AM, with two intravenous lines in place (one for the infusate and one for blood sampling), L- [5,5,5-D 3 ] leucine (10 mmol/kg body weight) was injected as an intravenous bolus and then by continuous infusion (10 mmol/kg body weight per hour) for a 12-hour period. Blood samples (24 mL) were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, and 12 hours. Data on sample processing, laboratory measurements, analysis of the lipoprotein PR, and fractional catabolic rate (FCR) are provided in the Supplemental Data.
Statistical analysis
Differences between treatments were assessed using the MIXED procedure for repeated measures, with treatment as fixed effect and a compound symmetry matrix to account for within-subject correlations (SAS, version 9.4; SAS Institute, Cary, NC). The change vs the control treatment (post-treatment DHA minus control and EPA minus control) was used as the dependent variable in all analyses. The main treatment effect in the mixed models reflected the direct comparison of DHA and EPA and was considered the primary analysis. Adjustment for multiple comparisons was not necessary, because the main treatment effect had only two levels (DHA and EPA). In the same model and as secondary analyses, the change vs control for each treatment was tested against the null hypothesis using the LSMEANS statement. The skewness in the distribution of model residuals was considered, and the data were log-transformed when required. Wilcoxon signed-rank tests were also performed to test for the difference in the change from control after DHA and EPA supplementation, with results similar to those generated by the mixed models (data not shown). Spearman coefficient correlations among the changes in apoB100-and apoCIII-containing lipoprotein kinetic parameters, PCSK9 levels, LDL-C, LDL-apoB100, and LDL size were computed.
Results
Data from one participant who was ill during the first kinetic study test were excluded from the analyses. The baseline characteristics of the 19 participants who completed at least one kinetic substudy and the participants of the whole sample who completed at least one study phase are presented in Table 1 . The characteristics of the subsample were similar to those of the whole group, with the exception that proportionally more women were included in the kinetic substudy. Among the participants of the kinetic substudy, one participant completed only one phase and two participants completed two study phases. The mean compliance rate based on the returned capsules was .95% for all study phases (data not shown). Among the 154 participants randomized to treatment sequences, 12 participants were taking statins. None were taking other lipid-lowering drugs. Pharmacotherapy remained unchanged in all participants throughout the study in the present crossover trial. None of the kinetic substudy participants were taking lipid-lowering drugs. Three participants had type 2 diabetes and one had type 1 diabetes; however, none of these participants were included in the substudy.
LDL particle size and PCSK9
Blood lipids and LDL particle size features before the control phase and after the three treatments are presented in Table 2 for all participants and for the substudy group only. The treatment-specific baseline values before DHA and EPA were essentially identical to the values measured before the control treatment and therefore were not presented. In all participants, DHA increased the mean LDL particle size (compared with the control: DHA, +0.32Å; EPA, 20.41Å; DHA vs EPA, P , 0.0001) and LDL peak particle size (compared with control: DHA, +0.58Å; EPA, 20.32Å; DHA vs EPA, P , 0.0001) more than did EPA. The change in the proportion of sdLDL was also significantly different statistically between EPA and DHA (compared with control: DHA, 21.10%; EPA, +2.10%; EPA vs DHA, P , 0.002). Both EPA and DHA decreased the PCSK9 concentrations similarly (compared with control: DHA, 225.0 ng/mL; EPA, 218.2 ng/mL; DHA vs EPA, P = 0.19). The changes in these cardiometabolic outcomes with DHA and EPA were generally similar in direction and magnitude among the participants of the substudy. However, only the difference between the change in the PCSK9 concentrations after DHA and EPA compared with control remained statistically significant in the subsample.
Kinetic studies
Both DHA and EPA tended to increase VLDL apoB100 FCR similarly compared with the control (DHA, +21%; EPA, +19%; DHA vs EPA, P = 0.73; Table 3 ). However, EPA tended to increase VLDL apoB100 direct catabolism more than did DHA (compared with control: DHA, 23%; EPA, +22%; DHA vs EPA, P = 0.10). Changes in the VLDL to LDL apoB100 conversion rates were similar after DHA and EPA (compared with control: DHA, +8%; EPA, +7%; DHA vs EPA, P = 0.44). LDL apoB100 FCR was significantly lower after EPA supplementation than after DHA supplementation (compared with control: DHA, 0%; EPA, 210%; DHA vs EPA, P = 0.008). In contrast, DHA increased the LDL apoB100 PR compared with EPA (compared with control: DHA, +2%; EPA, 27%; DHA vs EPA, P = 0.027).
The increase in LDL-C concentrations after DHA or EPA supplementation did not correlate with variations in the LDL apoB100 FCR or PR (Table 4) . However, variations in the LDL apoB100 pool size correlated with change in LDL apoB100 PR after EPA (rs = 0.63; P = 0.013) and with variations in LDL apoB100 FCR after DHA (rs = 20.52; P = 0.04) and PCSK9 concentration after DHA (rs = 0.64; P , 0.01).
Both DHA and EPA decreased VLDL apoCIII FCR similarly compared with the control (DHA, 211%; EPA, 27%; DHA vs EPA, P = 0.60). The reduction in VLDL apoCIII PR tended to be greater after DHA than after EPA (compared with control: DHA, 212%; EPA, +1%; DHA vs EPA, P = 0.09). The change in VLDL apoCIII FCR correlated inversely with the change in the PCSK9 concentration after EPA (rs = 20.58; P = 0.019; data not shown) and with the change in LDL apoB100 FCR after DHA (rs = 0.54; P = 0.030; data not shown). The change in VLDL apoCIII PR correlated inversely with LDL apoB100 FCR and PR (rs = 20.57 and rs = 20.53, respectively; P , 0.05; data not shown) and was positively associated with the change in PCSK9 concentrations after DHA (rs = 0.54; P = 0.021; data not shown). We did not find any correlation between the changes in TG and LDL-C or between the changes in VLDL apoCIII FCR and LDL apoB100 PR after DHA or EPA (data not shown).
Discussion
To the best of our knowledge, the present study is the first to demonstrate the mechanisms underlying the differential effects of DHA and EPA supplementation on LDL-C and other features of LDL in men and women with abdominal obesity and subclinical inflammation and at risk of CVD. The results from the present study suggest that high-dose DHA increases the LDL particle size and modifies LDL apoB100 and VLDL apoCIII kinetics compared with EPA. Although DHA and EPA reduce the PCSK9 concentration similarly, the relationships among PCSK9, LDL-C, and LDL apoB100 concentrations were different between DHA and EPA.
We have previously shown that the magnitude of the reduction in TG and increase in LDL-C after DHA was greater than after EPA supplementation (4). Previous in vivo kinetic studies have documented the effects of LCn3-PUFAs, either as a dietary supplement or as part of an LCn3-PUFA-rich diet, on apoB100-containing lipoprotein metabolism (27, 28) . Those studies have shown that LCn3-PUFAs reduce TG concentrations primarily by reducing the endogenous production of VLDL apoB100 and by increasing Data presented as mean 6 SD.
CRP values .10 were excluded (n = 5 for the whole cohort).
For the whole cohort, the baseline characteristics of participants who completed at least one study phase are presented.
Abbreviations: BMI, body mass index; C, cholesterol; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; SBP, systolic blood pressure. a For the whole cohort, n = 137.
the VLDL to LDL apoB100 conversion rate (27, 28) . LCn3-PUFAs have also been shown to increase the clearance of LDL apoB100 (27, 28) . In contrast, Ooi et al. (12) found that a high-fish diet (containing 1.23 g EPA plus DHA daily) increases LDL apoB100 production by 32% and concomitantly decreases LDL apoB100 clearance by 44% compared with untreated baseline values. This disproportionate reduction in LDL apoB100 clearance might explain in part why the LDL-C concentrations increase after LCn3-PUFA supplementation. Because the changes in LDL-C and TG concentrations are greater with DHA supplementation than with EPA supplementation (4), we hypothesized that DHA compared with EPA induces a greater reduction in VLDL apoB100 production and a greater VLDL to LDL apoB100 conversion rate, resulting in a greater increase in LDL apoB100 production. Accordingly, DHA compared with EPA differentially influenced LDL apoB100 production and clearance rates; however, these differences were not related to the differential effects of DHA and EPA on LDL-C concentrations. DHA and EPA equally increased VLDL to LDL apoB100 conversion and VLDL apoB100 FCR. These data suggest that metabolic pathways not involving apoB100 per se might be responsible for the differential effects of DHA and EPA on LDL-C concentrations and LDL size. It is possible that DHA and EPA differentially influence apoB/C/E ratios on VLDL, which might, in turn, contribute to differences in the LDL-C concentrations and LDL size seen between DHA and EPA (6, 7). Zheng et al. (7) have shown that apoCIII-containing VLDL are the major precursor of LDL particles. Hence, the suppression of apoCIII PR with DHA might also explain to some extent its effect on LDL particle size. That total VLDL particles were converted more rapidly to intermediate-density lipoprotein after DHA than after EPA (Table 3) and that VLDL-apoCIII levels also tended to decrease with DHA compared with EPA is consistent with this hypothesis. We also hypothesized that DHA and EPA supplementation would modulate LDL particle size differently because the increase in LDL-C concentration after DHA d Log-transformed data were used in these analyses due to skewness of the distribution of the values.
e Previously reported (4).
f P , 0.05; because pre-DHA and -EPA values were essentially identical to the precontrol values, only precontrol values are presented. Models were adjusted for sex, weight, age, sequence; baseline value was considered only when these covariates were found to be significant at P , 0.05 in the models. g Participants equaled 19 for DHA, 17 for EPA, and 19 for control.
doi: 10.1210/jc.2017-02745 https://academic.oup.com/jcemwas almost twofold greater in magnitude than the increase in total apoB concentration (4). Accordingly, DHA supplementation slightly increased mean LDL particle size and decreased the proportion of sdLDL compared with EPA supplementation. This observation is consistent with data from a few studies, which have shown that DHA, but not EPA, is associated with larger LDL (9, 29) . This increase in LDL particle size after DHA can be attributed, at least in part, to the greater reduction in serum TG compared with EPA. Serum TG is an important metabolic determinant of the sdLDL phenotype through a series of metabolic transformation of the LDL particles that involve lipases and cholesteryl ester transfer protein (30). However, very few studies have compared the effect of DHA and EPA on enzyme activities. Supplementation with LCn3-PUFA has been shown to have inconsistent effects on cholesteryl ester transfer protein activity (31) and might increase lipoprotein lipase activity through upregulation of it expression (31) but might have no effect on hepatic lipase activity (31) . More studies investigating these pathways in response to DHA and EPA supplementations are needed.
The increase in LDL size with DHA compared with EPA might also be explained in part by a decrease in apoCIII secretion from the liver (32) . DHA might reduce apoCIII production through the regulation of the forkhead box O transcription factor O1 and carbohydrate response elementbinding protein (33, 34) . ApoCIII inhibits the binding of apoB to hepatic apoB/E receptor and lipoprotein lipase activity (32, 35) . In a small parallel study, supplementation with EPA alone tended to increase apoCIII concentrations, and DHA tended to decrease apoCIII-containing lipoprotein concentrations (36) . Consistent with this, we have shown that high-dose EPA also tended to increase VLDL apoCIII mass and DHA tended to decrease the VLDL apoCIII mass compared with the control, although the differences did not reach statistical significance. DHA also tended to decrease the VLDL apoCIII PR compared with EPA; however, the difference also did not reach the statistical significance. Changes in VLDL apoCIII metabolism correlated with changes in LDL apoB100 metabolism after DHA, but not after EPA, supporting a differential effect of EPA and DHA on VLDL apoCIII and apoB100 metabolism. This apparent reduction in apoCIII production in the liver after DHA supplementation might explain the enhanced conversion of VLDL to LDL apoB100 and the formation of larger LDL particles compared with EPA. Individuals with a preponderance of sdLDL have consistently been shown to be at increased risk of myocardial infarction and CVD compared with individuals with a greater proportion of larger LDL particles (37) . However, the extent to which the opposite effects of DHA on both LDL-C and LDL particle size modify CVD risk is unknown. The reduction in PCSK9 concentrations observed after DHA and EPA supplementation is consistent with data from the few available studies on this topic. A recent randomized controlled parallel study in 92 pre-and postmenopausal women has shown that supplementation with 2.2 g/d of marine oil decreased plasma PCSK9 concentrations by 11.4% in premenopausal women and 9.8% in postmenopausal women compared with baseline (19) . Post hoc analyses of the Canola Oil Multicenter Intervention Trial have also shown that the PCSK9 concentration was lower after DHA-enriched canola oil than after regular canola oil supplementation (20) . In the present study, DHA and EPA both reduced serum PCSK9 levels equally compared with the control. Although the PCSK9 concentrations usually correlated with LDL-C concentrations, variations in the PCSK9 levels explained ,8% of the LDL-C variance (38) . Furthermore, the PCSK9 concentrations might not fully reflect PCSK9 activity (38) . Therefore, the increase in LDL-C after DHA and EPA despite a decrease in PCSK9 concentrations was not entirely unexpected. In contrast, changes in PCSK9 correlated positively with changes in the LDL apoB100 concentrations and negatively with changes in LDL apoB100 FCR after DHA but not after EPA, suggesting that PCSK9 might be partly involved in explaining the differential effects of DHA and EPA supplementation on the metabolic fate of the LDL particle.
The present study had several strengths and limitations. A number of studies have examined the effect of an LCn3-PUFA-rich diet or a supplement combining EPA and DHA in various forms and proportions on apoB100-containing lipoprotein kinetics (27, 28) . To the best of our knowledge, ours is the first study to compare headto-head the effect of high-dose EPA and DHA on apoB100-containing lipoprotein kinetics. The use of a randomized crossover study design reduced the interindividual variability of the results. The baseline characteristics of the kinetic subsample were similar to the whole study cohort, and the compliance was high in all phases of the study (4) . The analyses of the changes in blood lipids, LDL particle size, and PCSK9 concentrations in the substudy kinetic sample were conducted on data from fewer participants, hence influencing the statistical power. Estimates from small kinetic pool sizes have relatively high coefficients of variations and small changes in kinetic parameters can be difficult to assess. The observed effects of DHA and EPA on serum lipids, including LDL-C, might have resulted from changes in kinetics that might have been too subtle to be detected with this sample size. Corn oil was chosen as the control because of the relatively neutral effects of n6-PUFA on inflammation makers (39) , which were the primary outcome of the trial (4). Supplementation with the control n6-PUFA-rich corn oil decreased total cholesterol (20.12 mmol/L; P = 0.001), LDL-C (20.13 mmol/L; P = 0.003), and mean LDL size (20.22Å; P = 0.02) compared with control-specific baseline levels. However, results were similar when the change from DHA/EPA-specific baseline values were considered. Specifically, the increase in LDL-C and the reduction in TG with DHA compared with the baseline values were significantly greater than those seen with EPA (LDL-C, +0.11 vs 0.00 mmol/L; TG, 20.26 vs 20.20 mmol/L; P , 0.01 for all). The increase from treatment-specific baseline values in LDL particle size (+0.21Å vs 20.71Å) and the reduction in the proportion of sdLDL (21.36% vs +2.8%) were also greater with DHA than with EPA (P , 0.01 for all; data not shown). Because very few studies have documented the effect of n6-PUFA on apoB100-and apoCIII-containing lipoprotein metabolism, it is difficult to assess how the use of corn oil as the control treatment has affected the kinetic study data (27, 28, 40) .
In conclusion, the differential effects of DHA and EPA supplementation on LDL-C concentrations might not be accounted for by differences in the regulation of apoB100-containing lipoprotein metabolism and might involve other pathways that influence LDL particle size. The extent to which the greater increase in LDL-C with DHA compared with EPA, associated with larger LDL particles, influences CVD risk is unknown. Further studies are needed to better understand the changes in other metabolic factors after EPA and DHA supplementation, including the expression of the different genes involved in lipid metabolism.
